NCAM1 and Miyoshi myopathy: One multicenter study which enrolled 35 patients with NDMM carrying t (14;16) and 124 patients without t (14;16) as a control indicated that lack of CD56 expression was a poor prognostic factor for MM patients with t (14;16) in novel-agent era [17].